DK3253762T3 - 9h-pyrrolo-dipyridinderivater. - Google Patents
9h-pyrrolo-dipyridinderivater. Download PDFInfo
- Publication number
- DK3253762T3 DK3253762T3 DK16702121.1T DK16702121T DK3253762T3 DK 3253762 T3 DK3253762 T3 DK 3253762T3 DK 16702121 T DK16702121 T DK 16702121T DK 3253762 T3 DK3253762 T3 DK 3253762T3
- Authority
- DK
- Denmark
- Prior art keywords
- pyrrolo
- dipyridine
- derivatives
- dipyridine derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15153448 | 2015-02-02 | ||
| PCT/EP2016/051993 WO2016124508A1 (en) | 2015-02-02 | 2016-01-29 | 9h-pyrrolo-dipyridine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3253762T3 true DK3253762T3 (da) | 2021-07-19 |
Family
ID=52477553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16702121.1T DK3253762T3 (da) | 2015-02-02 | 2016-01-29 | 9h-pyrrolo-dipyridinderivater. |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20180022748A1 (enExample) |
| EP (1) | EP3253762B1 (enExample) |
| JP (1) | JP6579670B2 (enExample) |
| KR (1) | KR102621513B1 (enExample) |
| CN (1) | CN107207508B (enExample) |
| AU (1) | AU2016214537B2 (enExample) |
| BR (1) | BR112017016311A2 (enExample) |
| CA (1) | CA2973648C (enExample) |
| CL (1) | CL2017001923A1 (enExample) |
| DK (1) | DK3253762T3 (enExample) |
| EA (1) | EA036518B1 (enExample) |
| ES (1) | ES2875734T3 (enExample) |
| IL (1) | IL253381B (enExample) |
| MX (1) | MX378155B (enExample) |
| MY (1) | MY191590A (enExample) |
| SG (1) | SG11201705727TA (enExample) |
| WO (1) | WO2016124508A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2599763A1 (en) | 2008-02-14 | 2013-06-05 | Siemens Molecular Imaging, Inc. | Novel imaging agents for detecting neurological dysfunction |
| US20180022748A1 (en) * | 2015-02-02 | 2018-01-25 | Ucb Biopharma Sprl | 9h-pyrrolo-dipyridine derivatives |
| EP3487545A1 (en) * | 2016-07-22 | 2019-05-29 | AC Immune S.A. | Compounds for imaging tau protein aggregates |
| WO2018015549A1 (en) | 2016-07-22 | 2018-01-25 | Ac Immune S.A. | Compounds for imaging tau protein aggregates |
| WO2018046428A1 (en) * | 2016-09-09 | 2018-03-15 | F. Hoffmann-La Roche Ag | Process for preparation of 2-(6-nitropyridin-3-yl)-9h-dipyrido[2,3-b;3',4'-d]pyrrole |
| MX2019005007A (es) * | 2016-11-01 | 2019-07-18 | Arvinas Inc | Protac dirigidos a la proteína tau y métodos asociados de uso. |
| CN110691594A (zh) * | 2017-06-02 | 2020-01-14 | 富士胶片富山化学株式会社 | Tau蛋白病预防或治疗剂 |
| JP7282028B2 (ja) | 2017-06-02 | 2023-05-26 | 富士フイルム富山化学株式会社 | 脳萎縮予防または治療剤 |
| RU2728717C1 (ru) | 2017-06-02 | 2020-07-30 | ФУДЖИФИЛМ Тояма Кемикал Ко., Лтд. | Средство для профилактики или лечения спиноцеребеллярной атаксии |
| US11541033B2 (en) | 2017-06-02 | 2023-01-03 | Fujifilm Toyama Chemical Co., Ltd. | Agent for preventing or treating Alzheimer's disease |
| KR20200003102A (ko) | 2017-06-02 | 2020-01-08 | 후지필름 도야마 케미컬 가부시키가이샤 | 아밀로이드 β 단백질량 감소제 |
| JP7227914B2 (ja) | 2017-10-30 | 2023-02-22 | 富士フイルム富山化学株式会社 | エモパミル結合タンパク質結合剤およびその利用 |
| JP7659988B2 (ja) * | 2018-01-24 | 2025-04-10 | エーシー・イミューン・エス・アー | 画像化化合物を調製する新規方法 |
| EP3743426A1 (en) * | 2018-01-24 | 2020-12-02 | AC Immune SA | Azacarboline compounds for the detection of tau aggregates |
| WO2019145291A1 (en) | 2018-01-24 | 2019-08-01 | Ac Immune Sa | Gamma-carboline compounds for the detection of tau aggregates |
| EP3999182A1 (en) | 2019-07-17 | 2022-05-25 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated methods of use |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1268771A (en) | 1968-03-15 | 1972-03-29 | Glaxo Lab Ltd | Azacarbazoles |
| WO2008132454A1 (en) * | 2007-04-26 | 2008-11-06 | Ge Healthcare Limited | Carbolines and their use as imaging agents |
| EP2599763A1 (en) * | 2008-02-14 | 2013-06-05 | Siemens Molecular Imaging, Inc. | Novel imaging agents for detecting neurological dysfunction |
| EP2370407B1 (en) * | 2008-12-19 | 2014-06-18 | Bristol-Myers Squibb Company | Carbazole and carboline kinase inhibitors |
| JP5976206B2 (ja) * | 2012-05-22 | 2016-08-23 | イーライ リリー アンド カンパニー | 神経機能障害を検出するための造影剤 |
| WO2014194169A1 (en) * | 2013-05-31 | 2014-12-04 | The General Hospital Corporation | Radiosynthesis of tau radiopharmaceuticals |
| WO2015010263A1 (en) * | 2013-07-24 | 2015-01-29 | Telefonaktiebolaget L M Ericsson(Publ) | Method and apparautus relating to reception of radio signals |
| AU2014333996B2 (en) * | 2013-10-08 | 2018-03-15 | F. Hoffmann-La Roche Ag | Diazacarbazole derivatives as tau-pet-ligands |
| US10662193B2 (en) * | 2014-01-21 | 2020-05-26 | Ac Immune Sa | Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyloid-like proteins |
| US20180022748A1 (en) * | 2015-02-02 | 2018-01-25 | Ucb Biopharma Sprl | 9h-pyrrolo-dipyridine derivatives |
-
2016
- 2016-01-29 US US15/547,980 patent/US20180022748A1/en not_active Abandoned
- 2016-01-29 EP EP16702121.1A patent/EP3253762B1/en active Active
- 2016-01-29 MX MX2017009505A patent/MX378155B/es unknown
- 2016-01-29 AU AU2016214537A patent/AU2016214537B2/en active Active
- 2016-01-29 DK DK16702121.1T patent/DK3253762T3/da active
- 2016-01-29 CN CN201680008314.3A patent/CN107207508B/zh active Active
- 2016-01-29 MY MYPI2017702668A patent/MY191590A/en unknown
- 2016-01-29 EA EA201791733A patent/EA036518B1/ru not_active IP Right Cessation
- 2016-01-29 BR BR112017016311A patent/BR112017016311A2/pt not_active Application Discontinuation
- 2016-01-29 ES ES16702121T patent/ES2875734T3/es active Active
- 2016-01-29 CA CA2973648A patent/CA2973648C/en active Active
- 2016-01-29 JP JP2017540724A patent/JP6579670B2/ja active Active
- 2016-01-29 KR KR1020177024371A patent/KR102621513B1/ko active Active
- 2016-01-29 WO PCT/EP2016/051993 patent/WO2016124508A1/en not_active Ceased
- 2016-01-29 SG SG11201705727TA patent/SG11201705727TA/en unknown
-
2017
- 2017-07-10 IL IL253381A patent/IL253381B/en active IP Right Grant
- 2017-07-27 CL CL2017001923A patent/CL2017001923A1/es unknown
-
2020
- 2020-01-22 US US16/749,537 patent/US11312716B2/en active Active
-
2022
- 2022-03-21 US US17/700,075 patent/US12006316B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112017016311A2 (pt) | 2018-03-27 |
| JP2018503673A (ja) | 2018-02-08 |
| MY191590A (en) | 2022-06-30 |
| EA201791733A1 (ru) | 2018-01-31 |
| SG11201705727TA (en) | 2017-08-30 |
| CN107207508A (zh) | 2017-09-26 |
| ES2875734T3 (es) | 2021-11-11 |
| JP6579670B2 (ja) | 2019-09-25 |
| MX2017009505A (es) | 2017-11-02 |
| CN107207508B (zh) | 2020-02-28 |
| WO2016124508A1 (en) | 2016-08-11 |
| IL253381B (en) | 2020-10-29 |
| KR20170113607A (ko) | 2017-10-12 |
| US12006316B2 (en) | 2024-06-11 |
| CA2973648C (en) | 2023-09-26 |
| AU2016214537A1 (en) | 2017-08-03 |
| US20220213103A1 (en) | 2022-07-07 |
| CA2973648A1 (en) | 2016-08-11 |
| KR102621513B1 (ko) | 2024-01-04 |
| US20210047326A1 (en) | 2021-02-18 |
| EA036518B1 (ru) | 2020-11-18 |
| AU2016214537B2 (en) | 2018-05-10 |
| MX378155B (es) | 2025-03-10 |
| IL253381A0 (en) | 2017-09-28 |
| CL2017001923A1 (es) | 2018-02-16 |
| EP3253762A1 (en) | 2017-12-13 |
| US11312716B2 (en) | 2022-04-26 |
| US20180022748A1 (en) | 2018-01-25 |
| EP3253762B1 (en) | 2021-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3319956T3 (da) | Substituerede oxopyridinderivater | |
| PL3345230T3 (pl) | Podwójny perowskit | |
| DK3283625T3 (da) | Nukleasemedieret genomeditering | |
| DK3331869T3 (da) | Muscarinagonister | |
| LT3230281T (lt) | 1,3-tiazol-2-ilu pakeisti benzamidai | |
| DK3331528T3 (da) | Muskarinagonister | |
| DK3277719T3 (da) | Polypeptider | |
| DK3360890T3 (da) | Genterapi | |
| DK3305788T3 (da) | Janus-kinase-hæmmer | |
| DK3331529T3 (da) | Muskarinagonister | |
| EP3713931C0 (en) | 3-OXO-6-HETEROARYL-2-PHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDE | |
| DK3310450T3 (da) | Olie-vand-separator | |
| NL301307I2 (nl) | fruquintinib | |
| LT3457851T (lt) | Sobetiromo dariniai | |
| LT3402792T (lt) | Chinolin-2-ono dariniai | |
| DK3270930T3 (da) | Præeklampsi | |
| BR112017001387A2 (pt) | alargador. | |
| BR112017001386A2 (pt) | alargador. | |
| FR3023988B3 (fr) | . | |
| LT3371168T (lt) | Indolin-2-ono dariniai | |
| BR112017001389A2 (pt) | alargador. | |
| BR112017001388A2 (pt) | alargador. | |
| DK3292136T3 (da) | Penicillin-g-acylaser | |
| DK3274482T3 (da) | Stenborsknop | |
| IT201600084952A1 (it) | Coglifrutta. |